AbbVie says multiple parties vying for assets related to Allergan deal approval

AbbVie Inc <ABBV.N> said on Friday it was in talks with several parties interested in buying the two assets it intends to divest for the completion of its $63 billion deal to buy drugmaker Allergan Plc <AGN.N>.

The company said it had notified the U.S. antitrust watchdog of its intention to divest its experimental inflammatory bowel disease therapy, brazikumab, and its treatment for a type of pancreatic disease, Zenpep.